Janssen Applies for Single Tablet Combo for Treatment of Patients with Pulmonary Arterial Hypertension

 This is the first and only single tablet combination therapy application to be submitted for review in the U.S. for this rare, progressive disease  

If approved, Janssen's comprehensive PAH portfolio has the potential to cover all guidelines-recommended treatment pathways

https://www.biospace.com/article/releases/janssen-submits-new-drug-application-to-u-s-fda-seeking-approval-of-investigational-single-tablet-combination-therapy-of-macitentan-and-tadalafil-for-treatment-of-patients-with-pulmonary-arterial-hypertension-pah-/